- Home
- IDR vs AURA Comparison
IDR vs AURA Comparison
Compare IDR & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDR | AURA |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.0M | 396.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | IDR | AURA |
|---|---|---|
| Price | $44.97 | $5.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $17.50 | ★ $20.20 |
| AVG Volume (30 Days) | ★ 438.7K | 189.1K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.70 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $35,424,313.00 | N/A |
| Revenue This Year | $21.91 | N/A |
| Revenue Next Year | $5.47 | N/A |
| P/E Ratio | $59.16 | ★ N/A |
| Revenue Growth | ★ 61.35 | N/A |
| 52 Week Low | $9.67 | $4.35 |
| 52 Week High | $54.70 | $8.72 |
Technical Indicators
Market Signals| Indicator | IDR | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 65.76 | 43.00 |
| Support Level | $41.65 | $6.27 |
| Resistance Level | $46.33 | $6.69 |
| Average True Range (ATR) | 3.21 | 0.28 |
| MACD | 0.45 | -0.07 |
| Stochastic Oscillator | 95.59 | 10.31 |
Price Performance
Historical ComparisonAbout IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.